Intranasal delivery of caspase-9 inhibitor reduces caspase-6-dependent axon/neuron loss and improves neurological function after stroke

J Neurosci. 2011 Jun 15;31(24):8894-904. doi: 10.1523/JNEUROSCI.0698-11.2011.

Abstract

Despite extensive research to develop an effective neuroprotective strategy for the treatment of ischemic stroke, therapeutic options remain limited. Although caspase-dependent death is thought to play a prominent role in neuronal injury, direct evidence of active initiator caspases in stroke and the functional relevance of this activity have not previously been shown. Using an unbiased caspase-trapping technique in vivo, we isolated active caspase-9 from ischemic rat brain within 1 h of reperfusion. Pathogenic relevance of active caspase-9 was shown by intranasal delivery of a novel cell membrane-penetrating highly specific inhibitor for active caspase-9 at 4 h postreperfusion (hpr). Caspase-9 inhibition provided neurofunctional protection and established caspase-6 as its downstream target. The temporal and spatial pattern of expression demonstrates that neuronal caspase-9 activity induces caspase-6 activation, mediating axonal loss by 12 hpr followed by neuronal death within 24 hpr. Collectively, these results support selective inhibition of these specific caspases as an effective therapeutic strategy for stroke.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Intranasal
  • Aldehydes / pharmacology
  • Animals
  • Brain Infarction / drug therapy
  • Brain Infarction / etiology
  • Caspase 6 / deficiency
  • Caspase 6 / physiology*
  • Caspase 9 / metabolism
  • Caspase Inhibitors
  • Cysteine Proteinase Inhibitors / therapeutic use
  • Disease Models, Animal
  • Enzyme Inhibitors / therapeutic use*
  • Hippocampus / metabolism
  • Hippocampus / pathology
  • Humans
  • In Vitro Techniques
  • Infarction, Middle Cerebral Artery* / complications
  • Infarction, Middle Cerebral Artery* / drug therapy
  • Infarction, Middle Cerebral Artery* / pathology
  • Inhibitor of Apoptosis Proteins / chemistry
  • Inhibitor of Apoptosis Proteins / genetics
  • Inhibitor of Apoptosis Proteins / therapeutic use*
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Nerve Tissue Proteins / metabolism
  • Nervous System Diseases* / drug therapy
  • Nervous System Diseases* / etiology
  • Nervous System Diseases* / pathology
  • Neurons / pathology*
  • PTEN Phosphohydrolase / chemistry
  • PTEN Phosphohydrolase / genetics
  • PTEN Phosphohydrolase / therapeutic use
  • Rats
  • Rats, Wistar
  • Time Factors

Substances

  • Aldehydes
  • Caspase Inhibitors
  • Cysteine Proteinase Inhibitors
  • Enzyme Inhibitors
  • Inhibitor of Apoptosis Proteins
  • Nerve Tissue Proteins
  • PTEN Phosphohydrolase
  • Caspase 6
  • Caspase 9
  • 4-hydroxy-2-nonenal